Related Experiment Videos
Inflammation, autotoxicity and Alzheimer disease
1Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver, B.C., Canada. mcgeerpl@interchange.ubc.ca
Neurobiology of Aging
|January 5, 2002
Summary
Neuroinflammation drives Alzheimer disease (AD) through neuronal autotoxicity. Targeting inflammatory mediators, including COX-1, shows promise for AD treatment.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Neuroinflammation is a key characteristic of Alzheimer disease (AD).
- This involves an innate immune response leading to self-attack on neurons, termed autotoxicity.
- Numerous compounds in the AD brain sustain inflammatory responses.
Purpose of the Study:
- To explore therapeutic strategies targeting neuroinflammation in Alzheimer disease.
- To identify potential orally effective agents for AD treatment by counteracting inflammatory stimulators.
Main Methods:
- Review of identified compounds in the AD brain that promote inflammation.
- Analysis of epidemiological evidence and pilot clinical trials for NSAIDs.
- Theoretical consideration of interventions targeting core inflammatory mediators.
Main Results:
- Identified inflammatory mediators include beta-amyloid, pentraxins, complement proteins, cytokines (IL-1, IL-6, TNF-alpha), protease inhibitors, and COX-1/COX-2.
- Epidemiological data and pilot trials suggest promise for COX-1 inhibiting NSAIDs.
- Intervention in mediators closer to core processes may offer greater therapeutic potential.
Conclusions:
- Orally effective agents counteracting inflammatory stimulators are likely effective in treating AD.
- Traditional COX-1 inhibiting NSAIDs show promise for AD therapy.
- Targeting core inflammatory mediators presents significant therapeutic opportunities for Alzheimer disease.